CureVac SE, et al. v. BioNTech SE, et al.

  1. August 08, 2025

    GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal

    British pharmaceutical company GlaxoSmithKline said Friday it stands to make up to $500 million from settlements between German biotech companies CureVac and BioNTech after their legal disputes were squashed by a merger.

  2. August 07, 2025

    BioNTech's Acquisition Of CureVac Ends COVID Vax Case

    CureVac's case alleging Pfizer and BioNTech infringed patents related to messenger RNA technology is set to be dismissed after BioNTech announced in June that it would be acquiring CureVac, canceling what would have been the first-ever trial over COVID-19 vaccine patents in the U.S.

  3. December 10, 2024

    BioNTech, Pfizer Rival Wants Party Flip In COVID Vax IP Fight

    German biotech company CureVac asked a Virginia federal judge to flip the positions of the litigants in its COVID-19 vaccine patent fight with rivals Pfizer and BioNTech, saying the case had morphed into an infringement suit involving 10 CureVac patents.

  4. August 20, 2024

    Vax Patent Battles Heat Up As Attention On Pandemic Wanes

    It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.

  5. April 25, 2024

    CureVac, Acuitas Reach Deal In COVID Vax Patent Dispute

    CureVac SE told a Virginia federal judge Thursday that it has reached a settlement to resolve Acuitas Therapeutics Inc.'s lawsuit inventorship credit on patents related to lipid nanoparticle technology used to develop the blockbuster Pfizer and BioNTech COVID-19 vaccine.

  6. April 15, 2024

    Hold This COVID Vax Patent Case, Judge Recommends

    One of the suits over Pfizer's blockbuster COVID-19 vaccine hit a snag in Virginia federal court Friday when a judge recommended pausing the case to wait for a ruling in a related dispute over patent ownership involving one of BioNTech's other partners.

  7. May 19, 2023

    CureVac Lobs Infringement Counterclaims At BioNTech, Pfizer

    CureVac on Friday accused BioNTech and Pfizer of infringing nine of its patents covering COVID-19 technology, lodging counterclaims in the pharmaceutical companies' case, which was recently transferred from Massachusetts to Virginia federal court.